A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.

Autor: Peng, Xin1,2 (AUTHOR), Huang, Xin1,2 (AUTHOR), Lulu, Talal Ben3 (AUTHOR), Jia, Wenqing1,2 (AUTHOR), Zhang, Shaolu1,2,4 (AUTHOR), Cohen, Limor3 (AUTHOR), Huang, Shengfan1,2 (AUTHOR), Fan, Jindian1,2 (AUTHOR), Chen, Xi5,6 (AUTHOR), Liu, Shanshan1,2 (AUTHOR), Wang, Yongzhe1,2 (AUTHOR), Wang, Kailin1,2 (AUTHOR), Isoyama, Sho7 (AUTHOR), Dan, Shingo7 (AUTHOR), Wang, Feng8 (AUTHOR), Zhang, Zhe1,2 (AUTHOR) zhangzhe@tmu.edu.cn, Elkabets, Moshe3 (AUTHOR) moshee@bgu.ac.il, Kong, Dexin1,2,9,10 (AUTHOR) kongdexin@tmu.edu.cn
Zdroj: Molecular Cancer. 3/14/2024, Vol. 23 Issue 1, p1-23. 23p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje